Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the Shares.

Baijin Life Science Holdings Limited

佰金生命科學控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1466)

COMPLETION OF ISSUE OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcements of Baijin Life Science Holdings Limited (the "**Company**") dated 29 September 2025 and 22 October 2025 in relation to the issue of new Shares under General Mandate (the "**Announcements**"). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

COMPLETION OF THE SUBSCRIPTIONS

The Board is pleased to announce that the conditions precedent set out in the Subscription Agreements have been fulfilled and the Completion took place on 28 November 2025. Upon Completion, an aggregate of 40,000,000 Subscription Shares are allotted and issued to the Subscribers at the Subscription Price of HK$0.48 per Subscription Share pursuant to the terms and conditions of the Subscription Agreements.

The amount of gross proceeds from the Subscriptions is HK$19,200,000 and the net proceeds from the Subscriptions (after deduction of the relevant expenses) is approximately HK$19,100,000. It is expected that 60% of the net proceeds (approximately HK$11.5 million) from the Subscription shall be utilized for the repayment of bank borrowings, other borrowings and other payable, and the remaining 40% of the net proceeds (approximately HK$7.6 million) shall be utilized as general working capital of the Group including audit and professional fees, payroll and rental payment.

EFFECTS ON SHAREHOLDING STRUCTURE OF THE COMPANY

The shareholding structure of the Company (i) immediately before the Completion and (ii) immediately after the Completion is as follows:

	Immediately before Completion		**Immediately after Completion**	
	Number of Shares	*Approximate %*	*Number of Shares*	*Approximate %*
Ketto Inform Limited *(Note 1)*	159,817,351	17.91	159,817,351	17.14
Pacific Wish Limited *(Note 2)*	84,088,691	9.42	84,088,691	9.02
Public Shareholders				
Subscribers				
Liu Weidong (劉衛東)	—	—	20,000,000	2.15
Zhou Suya (周蘇雅)	—	—	19,000,000	2.04
Wang Huiqin (王會芹)	—	—	1,000,000	0.11
Other public Shareholders	648,348,043	72.67	648,348,043	69.54
Total	892,254,085	100.00	932,254,085	100.00

Notes:

1. These shares are directly owned by Ketto Inform Limited, and in turn, Ketto Inform Limited is owned by 41 individual ultimate beneficial owners.

2. These 84,088,691 Shares are directly owned by Pacific Wish Limited, which are legally and beneficially owned by Mr. Chan Vincent Wing Sing ("**Mr. Chan**") as to 50% and Ms. Hui Ka Man Emily ("**Ms. Hui**") as to 50%. As at the date of this announcement, the board of directors of Pacific Wish Limited comprises Mr. Chan and Ms. Hui.

By order of the Board
BAIJIN LIFE SCIENCE HOLDINGS LIMITED
Cheung Sze Ming
Executive Director

Hong Kong, 28 November 2025

As at the date of this announcement, the Board comprises Mr. Cheung Sze Ming, Mr. Dong Peng and Dr. Su Yaoyao as executive Directors; Mr. Zhu Yongjun, Mr. Cheng Chi Kin and Ms. Xie Chunchen as non-executive Directors; Mr. Wong Siu Keung Joe, Mr. Chang Chunyu and Mr. Lee Ka Leung Daniel as independent non-executive Directors.